Sponsored Videos

YPrime President, Mark Maietta, discusses the future of decentralized clinical trials following Covid-19. Adaptations will need to be made as DCT is here to stay.

R&D growth from biotech and emerging biopharma companies is strong. With that comes a transformation of the end-to-end services needed to meet the strategic, clinical, and operational needs of these smaller companies. Join this podcast to learn about clinical development and outsourcing trends that emerged in 2021 and a discussion of what to expect in 2022.

This video series discusses the impact of implementing risk-based quality management (RBQM) and decentralized clinical trials (DCTs) from the clinical operations point of view.

In a recent virtual roundtable discussion, industry experts Jim Streeter, Alison Holland, Hassan Kadhim, Craig Lipset, Josh Rose, and Craig Serra shared their insight on the challenges faced in implementing decentralized trials and how to address them. Along with the roundtable are video discussions covering the cost and feasibility of a toolkit approach to decentralized trials, the significance of minimizing burden to patients and sites, and the reality of regulatory hurdles.

ACT’s Lisa Henderson interviews John Potthoff, PhD, CEO of Elligo Health Research, about decentralizing and restarting clinical trials amid the COVID-19 pandemic.